Jörn C Albring (Jörn Albring)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Blood advances

Bone marrow transplantation

Cancers

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Universitätsklinikum Münster

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universitätsklinikum Münster Jan 01 2013

Germany

Physician :: Department of Medicine A, Hematology, Oncology and Pneumology

Washington University in Saint Louis Feb 01 2006 - Nov 30 2012

United States

Postdoctoral Fellow :: Department of Pathology and Immunology

Publications

Philipp Berning, Lina Kolloch, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jörn C Albring, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone marrow transplantation 59 (8) (2024)
Karin Frebel, Jörn C Albring, Anika Wohlgemuth, Christian Schwöppe, Stephan Hailfinger, Georg Lenz, Matthias Stelljes
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood advances 8 (8) (2024)
Philipp Berning, Lina Kolloch, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jörn C Albring, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone marrow transplantation 59 (8) (2024)
Karin Frebel, Jörn C Albring, Anika Wohlgemuth, Christian Schwöppe, Stephan Hailfinger, Georg Lenz, Matthias Stelljes
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood advances 8 (8) (2024)
Jörn C Albring, Karin Frebel, Anika Wohlgemuth, Christian Schwöppe, Stephan Hailfinger, Georg Lenz, Matthias Stelljes
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood advances (2024)
Philipp Berning, Lina Kolloch, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jörn C Albring, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone marrow transplantation 59 (8) (2024)
Karin Frebel, Jörn C Albring, Anika Wohlgemuth, Christian Schwöppe, Stephan Hailfinger, Georg Lenz, Matthias Stelljes
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model. Blood advances 8 (8) (2024)
Philipp Berning, Lina Kolloch, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jörn C Albring, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone marrow transplantation (2024)
David Bernard Miklos, Mohammad Abu Zaid, Julian P Cooney, Jörn C Albring, Mary Evelyn Flowers, Alan P Skarbnik, Ibrahim Yakoub-Agha, Bor-Sheng Ko, Benedetto Bruno, Edmund K Waller, Jean A Yared, Sang Kyun Sohn, Claude-Eric Bulabois, Takanori Teshima, David Jacobsohn, Hildegard Greinix, Ahmad Mokatrin, Yihua Lee, Justin T Wahlstrom, Lori Styles, Gerard Sociè
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Christoph Schliemann, Mirjam Gerwing, Hauke Sebastian Heinzow, Saliha Harrach, Christian Schwöppe, Moritz Wildgruber, Anna A Hansmeier, Linus Angenendt, Andrew F Berdel, Ursula Stalmann, Björna Berning, Karsten Kratz-Albers, Kristina Middelberg-Bisping, Stefanie Wiebe, Jörn C Albring, Christian Wilms, Wolfgang Hartmann, Eva Wardelmann, Tobias Krähling, Walter Heindel, Joachim Gerß, Eike Bormann, Hartmut Schmidt, Georg Lenz, Torsten Kessler, Rolf M Mesters, Wolfgang E Berdel
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers 12 (6) (2020)

Jörn C Albring.css-eqlu8i{font-size:small;padding-left:4px;} (Jörn Albring)

Publication Activity (10 Years)

Top Topics

Top Venues

Jörn C Albring (Jörn Albring)